{"downloaded": true, "htmlmade": false, "id": "34443328", "source": "MED", "pmid": "34443328", "pmcid": "PMC8402032", "fullTextIdList": {"fullTextId": "PMC8402032"}, "doi": "10.3390/molecules26164740", "title": "Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines.", "authorString": "Gabano E, Pinton G, Balzano C, Boumya S, Osella D, Moro L, Ravera M.", "authorList": {"author": [{"fullName": "Gabano E", "firstName": "Elisabetta", "lastName": "Gabano", "initials": "E", "authorId": {"@type": "ORCID", "#text": "0000-0002-1181-1955"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy."}}}, {"fullName": "Pinton G", "firstName": "Giulia", "lastName": "Pinton", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dipartimento di Scienze del Farmaco, Universit\u00e0 del Piemonte Orientale, Largo Donegani 2/3, 28100 Novara, Italy."}}}, {"fullName": "Balzano C", "firstName": "Cecilia", "lastName": "Balzano", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy."}, {"affiliation": "Dipartimento di Scienze del Farmaco, Universit\u00e0 del Piemonte Orientale, Largo Donegani 2/3, 28100 Novara, Italy."}]}}, {"fullName": "Boumya S", "firstName": "Sara", "lastName": "Boumya", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dipartimento di Scienze del Farmaco, Universit\u00e0 del Piemonte Orientale, Largo Donegani 2/3, 28100 Novara, Italy."}}}, {"fullName": "Osella D", "firstName": "Domenico", "lastName": "Osella", "initials": "D", "authorId": {"@type": "ORCID", "#text": "0000-0002-6706-9454"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy."}}}, {"fullName": "Moro L", "firstName": "Laura", "lastName": "Moro", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dipartimento di Scienze del Farmaco, Universit\u00e0 del Piemonte Orientale, Largo Donegani 2/3, 28100 Novara, Italy."}}}, {"fullName": "Ravera M", "firstName": "Mauro", "lastName": "Ravera", "initials": "M", "authorId": {"@type": "ORCID", "#text": "0000-0002-4732-7508"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0002-1181-1955"}, {"@type": "ORCID", "#text": "0000-0002-4732-7508"}, {"@type": "ORCID", "#text": "0000-0002-6706-9454"}]}, "dataLinksTagsList": {"dataLinkstag": "supporting_data"}, "journalInfo": {"issue": "16", "volume": "26", "journalIssueId": "3223611", "dateOfPublication": "2021 Aug", "monthOfPublication": "8", "yearOfPublication": "2021", "printPublicationDate": "2021-08-01", "journal": {"title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules", "medlineAbbreviation": "Molecules", "NLMid": "100964009", "ISSN": "1420-3049", "ESSN": "1420-3049"}}, "pubYear": "2021", "pageInfo": "4740", "abstractText": "Cisplatin is widely employed as a first-line chemotherapeutic agent for many solid tumors, including malignant pleural mesothelioma (MPM). However, its clinical use is limited by heavy side effects and acquired resistance, the latter being mainly related to enhanced DNA repair. Many clinical trials using combinations of platinum drugs and PARP-1 inhibitors (PARPis) have been carried out, with the hope that such combinations might lead to improved therapeutic efficacy against tumors. Here, the synthesis and efficacy in reducing MPM cell viability of four cisplatin-based Pt(IV) prodrugs containing the PARPi 3-aminobenzamide (3-ABA) fragment are described. The most promising conjugate is more effective than cisplatin or cisplatin/3-ABA combination, administered in equimolar doses, in inhibiting PARP-1 activity and inducing apoptosis in BRCA1/2 wild type MPM cells, grown as monolayer or as multicellular spheroids.", "affiliation": "Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy.", "publicationStatus": "epublish", "language": "eng", "pubModel": "Electronic", "pubTypeList": {"pubType": ["IM", "research-article", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Cell Line, Tumor"}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Cisplatin", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "Y"}, {"abbreviation": "CH", "qualifierName": "chemistry", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Agents", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "Y"}, {"abbreviation": "CH", "qualifierName": "chemistry", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Drug Screening Assays, Antitumor"}, {"majorTopic_YN": "N", "descriptorName": "Cell Survival", "meshQualifierList": {"meshQualifier": {"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Poly(ADP-ribose) Polymerase Inhibitors", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "Y"}, {"abbreviation": "CH", "qualifierName": "chemistry", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Mesothelioma, Malignant", "meshQualifierList": {"meshQualifier": {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "Y"}}}]}, "chemicalList": {"chemical": [{"name": "Antineoplastic Agents", "registryNumber": "0"}, {"name": "Cisplatin", "registryNumber": "Q20Q21Q62J"}, {"name": "Poly(ADP-ribose) Polymerase Inhibitors", "registryNumber": "0"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.3390/molecules26164740"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC8402032"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC8402032?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "0", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2021-09-06", "dateOfCreation": "2021-08-27", "firstIndexDate": "2021-08-28", "fullTextReceivedDate": "2021-08-30", "dateOfRevision": "2021-09-06", "electronicPublicationDate": "2021-08-05", "firstPublicationDate": "2021-08-05"}